

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

APC-H7 Mouse Anti-Human CD8 Clone SK1

RRID:AB_10682894

Type: Antibody

Proper Citation

BD Biosciences Cat# 561423, RRID:AB_10682894

Antibody Information

URL: http://antibodyregistry.org/AB_10682894

Proper Citation: BD Biosciences Cat# 561423, RRID:AB_10682894

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: APC-H7 Mouse Anti-Human CD8 Clone SK1

Description: This monoclonal targets CD8

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: SK1

Antibody ID: AB_10682894

Vendor: BD Biosciences

Catalog Number: 561423

Record Creation Time: 20250820T000737+0000

Record Last Update: 20250820T072629+0000

Ratings and Alerts

No rating or validation information has been found for APC-H7 Mouse Anti-Human CD8 Clone SK1.

No alerts have been found for APC-H7 Mouse Anti-Human CD8 Clone SK1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. *Frontiers in immunology*, 16, 1579925.

Kirkpatrick C, et al. (2025) Isolation of mitochondrial mutation-specific T cell receptors. *Journal of immunology* (Baltimore, Md. : 1950).

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T??cells. *Cell reports methods*, 3(1), 100388.

Wu HL, et al. (2023) Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. *Immunity*, 56(7), 1649.

Monaghan KA, et al. (2023) CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses. *iScience*, 26(7), 107173.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.